Patents by Inventor Godfrey RAINEY
Godfrey RAINEY has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220251204Abstract: The disclosure generally provides proteins that bind two epitopes (e.g., a first and a second epitope) and that are bivalent for binding to each of the first and second epitopes. The disclosure also provides for specific binding proteins, including antibodies, which bind to a target protein. The disclosure also provides compositions comprising such proteins, nucleic acid molecules encoding such proteins and methods of making such proteins. The disclosure provides methods of inducing an immune response in a subject as well as methods for treating or preventing cancer in a subject by administering the proteins, nucleic acid molecules and/or compositions to the subject.Type: ApplicationFiled: December 14, 2021Publication date: August 11, 2022Inventors: Srinath KASTURIRANGAN, Changshou GAO, Godfrey RAINEY, Michelle MORROW, Claire Louise DOBSON, Stacey DRABIC, Darren SCHOFIELD, Gianluca CARLESSO, Kristen POLLIZZI, Yariv MAZOR, Michael OBERST, Scott A. HAMMOND, Brian LOBO, Prakash MANIKWAR, Jonathan SEAMAN, Simon DOVEDI, Ronald HERBST
-
Publication number: 20220177554Abstract: This disclosure relates to combination therapies comprising anti-Pseudomonas Psl and PcrV binding molecules and related compositions, for use in prevention and treatment of Pseudomonas infection.Type: ApplicationFiled: November 15, 2021Publication date: June 9, 2022Inventors: Antonio DIGIANDOMENICO, Paul WARRENER, Charles STOVER, Bret SELLMAN, Ralph MINTER, Sandrine GUILLARD, Steven RUST, Mladen TOMICH, Vignesh VENKATRAMAN, Reena VARKEY, Li PENG, Melissa DAMSCHRODER, Partha S. CHOWDHURY, Nazzareno DIMASI, Ryan FLEMING, Binyam BEZABEH, Changshou GAO, Godfrey RAINEY, Cuihua GAO
-
Patent number: 11279759Abstract: The disclosure generally provides proteins that bind two epitopes (e.g., a first and a second epitope) and that are bivalent for binding to each of the first and second epitopes. The disclosure also provides for specific binding proteins, including antibodies, which bind to a target protein. The disclosure also provides compositions comprising such proteins, nucleic acid molecules encoding such proteins and methods of making such proteins. The disclosure provides methods of inducing an immune response in a subject as well as methods for treating or preventing cancer in a subject by administering the proteins, nucleic acid molecules and/or compositions to the subject.Type: GrantFiled: September 13, 2019Date of Patent: March 22, 2022Assignee: MedImmune, LLCInventors: Srinath Kasturirangan, Changshou Gao, Godfrey Rainey, Michelle Morrow, Claire Louise Dobson, Stacey Drabic, Darren Schofield, Gianluca Carlesso, Kristen Pollizzi, Yariv Mazor, Michael Oberst, Scott A. Hammond, Brian Lobo, Prakash Manikwar, Jonathan Seaman, Simon Dovedi, Ronald Herbst
-
Patent number: 11203633Abstract: This disclosure relates to polynucleotides encoding antibodies or antigen binding fragments thereof that bind to Pseudomonas PcrV as well as vectors and host cells comprising the same.Type: GrantFiled: February 13, 2020Date of Patent: December 21, 2021Assignee: MedImmune LimitedInventors: Antonio Digiandomenico, Paul Warrener, Charles Stover, Bret Sellman, Ralph Minter, Sandrine Guillard, Steven Rust, Mladen Tomich, Vignesh Venkatraman, Reena Varkey, Li Peng, Melissa Damschroder, Partha S. Chowdhury, Nazzareno Dimasi, Ryan Fleming, Binyam Bezabeh, Changshou Gao, Godfrey Rainey, Cuihua Gao
-
Publication number: 20210069341Abstract: This disclosure provides conjugate compounds comprising antibodies and fragments thereof engineered with one or more reactive cysteine residues and more specifically to conjugate compounds with therapeutic or diagnostic applications. The conjugate compounds comprise cysteine-engineered antibodies or fragments thereof conjugated, for example, with chemotherapeutic drugs, toxins, and detection labels such as radionuclides or fluorophores. The disclosure also provides methods of using the disclosed conjugate compounds for in vitro, in situ, ex vivo, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.Type: ApplicationFiled: August 14, 2020Publication date: March 11, 2021Inventors: Changshou GAO, Godfrey RAINEY, Cuihua GAO
-
Publication number: 20200317757Abstract: This disclosure relates to combination therapies comprising anti-Pseudomonas Psl and PcrV binding molecules and related compositions, for use in prevention and treatment of Pseudomonas infection.Type: ApplicationFiled: February 13, 2020Publication date: October 8, 2020Inventors: Antonio DIGIANDOMENICO, Paul WARRENER, Charles STOVER, Bret SELLMAN, Ralph MINTER, Sandrine GUILLARD, Steven RUST, Mladen TOMICH, Vignesh VENKATRAMAN, Reena VARKEY, Li PENG, Melissa DAMSCHRODER, Partha S. CHOWDHURY, Nazzareno DIMASI, Ryan FLEMING, Binyam BEZABEH, Changshou GAO, Godfrey RAINEY, Cuihua GAO
-
Patent number: 10744204Abstract: This disclosure provides conjugate compounds comprising antibodies and fragments thereof engineered with one or more reactive cysteine residues and more specifically to conjugate compounds with therapeutic or diagnostic applications. The conjugate compounds comprise cysteine-engineered antibodies or fragments thereof conjugated, for example, with chemotherapeutic drugs, toxins, and detection labels such as radionuclides or fluorophores. The disclosure also provides methods of using the disclosed conjugate compounds for in vitro, in situ, ex vivo, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.Type: GrantFiled: April 10, 2015Date of Patent: August 18, 2020Assignee: MedImmune, LLCInventors: Changshou Gao, Godfrey Rainey, Cuihua Gao
-
Publication number: 20200172622Abstract: The disclosure generally provides proteins that bind two epitopes (e.g., a first and a second epitope) and that are bivalent for binding to each of the first and second epitopes. The disclosure also provides for specific binding proteins, including antibodies, which bind to a target protein. The disclosure also provides compositions comprising such proteins, nucleic acid molecules encoding such proteins and methods of making such proteins. The disclosure provides methods of inducing an immune response in a subject as well as methods for treating or preventing cancer in a subject by administering the proteins, nucleic acid molecules and/or compositions to the subject.Type: ApplicationFiled: September 13, 2019Publication date: June 4, 2020Inventors: SRINATH KASTURIRANGAN, CHANGSHOU GAO, GODFREY RAINEY, MICHELLE MORROW, CLAIRE LOUISE DOBSON, STACEY DRABIC, DARREN SCHOFIELD, GIANLUCA CARLESSO, KRISTEN POLLIZZI, YARIV MAZOR, MICHAEL OBERST, SCOTT A. HAMMOND, BRIAN LOBO, PRAKASH MANIKWAR, JONATHAN SEAMAN, SIMON DOVEDI, RONALD HERBST
-
Patent number: 10597439Abstract: This disclosure relates to combination therapies comprising anti-Pseudomonas Psl and PcrV binding molecules and related compositions, for use in prevention and treatment of Pseudomonas infection.Type: GrantFiled: November 6, 2012Date of Patent: March 24, 2020Assignee: MEDIMMUNE LIMITEDInventors: Antonio Digiandomenico, Paul Warrener, Charles Stover, Bret Sellman, Ralph Minter, Sandrine Guillard, Steven Rust, Mladen Tomich, Vignesh Venkatraman, Reena Varkey, Li Peng, Melissa Damschroder, Partha Chowdhury, Nazzareno Dimasi, Ryan Fleming, Binyam Bezabeh, Changshou Gao, Godfrey Rainey, Cuihua Gao
-
Patent number: 10457732Abstract: The disclosure generally provides proteins that bind two epitopes (e.g., a first and a second epitope) and that are bivalent for binding to each of the first and second epitopes. The disclosure also provides for specific binding proteins, including antibodies, which bind to a target protein. The disclosure also provides compositions comprising such proteins, nucleic acid molecules encoding such proteins and methods of making such proteins. The disclosure provides methods of inducing an immune response in a subject as well as methods for treating or preventing cancer in a subject by administering the proteins, nucleic acid molecules and/or compositions to the subject.Type: GrantFiled: May 5, 2017Date of Patent: October 29, 2019Assignee: MEDIMMUNE, LLCInventors: Srinath Kasturirangan, Changshou Gao, Godfrey Rainey, Michelle Morrow, Claire Louise Dobson, Stacey Drabic, Darren Schofield, Gianluca Carlesso, Kristen Pollizzi, Yariv Mazor, Michael Oberst, Scott A. Hammond, Brian Lobo, Prakash Manikwar, Jonathan Seaman, Simon Dovedi, Ronald Herbst
-
Patent number: 10160812Abstract: The present invention relates to anti-HER2 binding molecules (e.g., antibodies and antigen binding fragments thereof), derived HER2-binding molecules (e.g., bispecific anti-HER2 antibodies), and antibody-drug conjugates (ADC) that bind the extracellular domain of the HER2 receptor. Also provided are pharmaceutical formulation comprising the disclosed compositions and method for the treating diseases associated with HER2-mediated signal transduction.Type: GrantFiled: April 10, 2015Date of Patent: December 25, 2018Assignee: MedImmune, LLCInventors: John Li, Nazzareno Dimasi, Steven Coats, Melissa Damschroder, Changshou Gao, Godfrey Rainey, Cuihua Gao, Dorin Toader, Lakshmaiah Gingipalli, Fengjiang Wang, Ryan Fleming, Binyam Bezabeh, Andy Qingan Yuan, Srinath Kasturirangan
-
Publication number: 20180169255Abstract: This disclosure provides conjugate compounds comprising antibodies and fragments thereof engineered with one or more reactive cysteine residues and more specifically to conjugate compounds with therapeutic or diagnostic applications. The conjugate compounds comprise cysteine-engineered antibodies or fragments thereof conjugated, for example, with chemotherapeutic drugs, toxins, and detection labels such as radionuclides or fluorophores. The disclosure also provides methods of using the disclosed conjugate compounds for in vitro, in situ, ex vivo, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.Type: ApplicationFiled: April 10, 2015Publication date: June 21, 2018Inventors: Changshou Gao, Godfrey Rainey, Cuihua Gao
-
Publication number: 20180085458Abstract: The invention features methods for treating Clostridium difficile infection (CDI), C. difficile associated disease, and symptoms thereof, featuring the use of antibodies having enhanced half-life that specifically bind C. difficile toxin A and/or toxin B. In one aspect, the invention provides a method of treating a C. difficile infection or C. difficile-associated disease in a subject, the method involving administering to the subject a combination of an anti-C. difficile toxin A antibody and an anti-C. difficile toxin B antibody having an alteration that increases the half-life of one or both antibodies relative to anti-C. difficile toxin A and B antibodies lacking the alteration. In one aspect, the invention features a composition comprising an equimolar mixture of an anti-toxin A antibody and an anti-toxin B antibody. The invention provides kits for treating a C. difficile infection or symptoms thereof.Type: ApplicationFiled: April 14, 2016Publication date: March 29, 2018Inventors: Andrew C NYBORG, Paul WARRENER, Godfrey RAINEY
-
Publication number: 20180022807Abstract: The disclosure generally provides proteins that bind two epitopes (e.g., a first and a second epitope) and that are bivalent for binding to each of the first and second epitopes. The disclosure also provides for specific binding proteins, including antibodies, which bind to a target protein. The disclosure also provides compositions comprising such proteins, nucleic acid molecules encoding such proteins and methods of making such proteins. The disclosure provides methods of inducing an immune response in a subject as well as methods for treating or preventing cancer in a subject by administering the proteins, nucleic acid molecules and/or compositions to the subject.Type: ApplicationFiled: May 5, 2017Publication date: January 25, 2018Applicant: MEDIMMUNE, LLCInventors: Srinath KASTURIRANGAN, CHANGSHOU GAO, GODFREY RAINEY, MICHELLE MORROW, CLAIRE LOUISE DOBSON, STACEY DRABIC, DARREN SCHOFIELD, GIANLUCA CARLESSO, KRISTEN POLLIZZI, YARIV MAZOR, MICHAEL OBERST, SCOTT A. HAMMOND, BRIAN LOBO, PRAKASH MANIKWAR, JONATHAN SEAMAN
-
Publication number: 20170291955Abstract: The present invention relates to anti-HER2 binding molecules (e.g., antibodies and antigen binding fragments thereof), derived HER2-binding molecules (e.g., bispecific anti-HER2 antibodies), and antibody-drug conjugates (ADC) that bind the extracellular domain of the HER2 receptor. Also provided are pharmaceutical formulation comprising the disclosed compositions and method for the treating diseases associated with HER2-mediated signal transduction.Type: ApplicationFiled: April 10, 2015Publication date: October 12, 2017Inventors: John Li, Nazzareno Dimasi, Steven Coats, Melissa Damschroder, Changshou Gao, Godfrey Rainey, Cuihua Gao, Dorin Toader, Lakshmaiah Gingipalli, Fengjiang Wang, Ryan Fleming, Binyam Bezabeh, Andy Qingan Yuan, Srinath Kasturirangan
-
Publication number: 20170183397Abstract: This disclosure relates to combination therapies comprising anti-Pseudomonas Psl and PcrV bispecific binding molecules and related compositions, for use in prevention and treatment of Pseudomonas infection.Type: ApplicationFiled: May 4, 2015Publication date: June 29, 2017Inventors: Antonio DIGIANDOMENICO, Paul WARRENER, Charles STOVER, Bret SELLMAN, Ralph MINTER, Sandrine GUILLARD, Steven RUST, Mladen TOMICH, Vignesh VENKATRAMAN, Reena VARKEY, Li PENG, Melissa DAMSCHRODER, Partha CHOWDHURY, Nazzareno DIMASI, Ryan FLEMING, Binyam BEZABEH, Changshou GAO, Godfrey RAINEY, Cuihua GAO
-
Patent number: RE49908Abstract: The disclosure generally provides proteins that bind two epitopes (e.g., a first and a second epitope) and that are bivalent for binding to each of the first and second epitopes. The disclosure also provides for specific binding proteins, including antibodies, which bind to a target protein. The disclosure also provides compositions comprising such proteins, nucleic acid molecules encoding such proteins and methods of making such proteins. The disclosure provides methods of inducing an immune response in a subject as well as methods for treating or preventing cancer in a subject by administering the proteins, nucleic acid molecules and/or compositions to the subject.Type: GrantFiled: June 30, 2021Date of Patent: April 9, 2024Assignee: MedImmune, LLCInventors: Srinath Kasturirangan, Changshou Gao, Godfrey Rainey, Michelle Morrow, Claire Louise Dobson, Stacey Drabic, Darren Schofield, Gianluca Carlesso, Kristen Pollizzi, Yariv Mazor, Michael Oberst, Scott A. Hammond, Brian Lobo, Prakash Manikwar, Jonathan Seaman, Simon Dovedi, Ronald Herbst